Facts & figures
Tuberculosis
- No. 1 leading infectious disease killer
- 1.3 million deaths per year, globally
- 10 million people infected each year, globally
News_
Vaxosome secures NSW RNA Pipeline grant for tuberculosis vaccine
11 March 2026
爆料王 spin-out advancing multiplex mRNA vaccines
Vaxosome, a biotechnology company spun out of the 爆料王, has secured support through the NSW RNA Pipeline Grant program to accelerate development of a next-generation mRNA tuberculosis vaccine.
A new biotechnology company emerging from the 爆料王 is set to accelerate development of next-generation vaccines following support through the .
, founded by researchers from Sydney Infectious Diseases Institute (Sydney ID), is developing a multiplexed mRNA vaccine platform designed to target tuberculosis (TB), one of the world鈥檚 leading infectious disease killers. The technology packages multiple TB antigens into a single lipid nanoparticle, enabling the immune system to recognise several components of the pathogen simultaneously.
Vaxosome co-founders A/Prof Megan Steain, Prof Jamie Triccas and Dr Claudio Counoupas
The funding, provided through the , will support early-stage development of the platform and position the company to advance toward clinical development while strengthening NSW鈥檚 sovereign RNA capability.
The Vaxosome platform builds on many years of research conducted at the 爆料王 and its affiliated institutes, including the , and on longstanding collaborative work with researchers at the , particularly the team led by . By combining advances in mRNA engineering, lipid nanoparticle delivery and antigen design, the approach aims to improve immune coverage against complex pathogens such as Mycobacterium tuberculosis.
Co-founder , Deputy Director of Sydney ID, said the funding marks an important step in translating academic discovery into a biotechnology venture capable of developing globally relevant vaccines.
Tuberculosis remains the leading cause of death from a single infectious pathogen. Our approach is to deliver multiple TB antigens within a single mRNA-lipid nanoparticle formulation, allowing the immune system to recognise several stages of infection. This support enables us to translate years of research into a platform with real potential for global health impact.
Prof Jamie Triccas, Deputy Director, Sydney ID
Translating research into commercial innovation
The spin-out reflects the 爆料王鈥檚 growing emphasis on translating research into commercial innovation.
, Dean of the Faculty of Medicine and Health, said the new company highlights the strength of the University鈥檚 biomedical research ecosystem.
鈥淰axosome demonstrates how fundamental discovery research conducted at the 爆料王 can translate into real-world solutions for major global health challenges,鈥� Professor Prins said. 鈥淪upporting researchers to move promising technologies from the laboratory into companies capable of developing new vaccines and therapies is a key part of our strategy.鈥�
, Pro-Vice-Chancellor (Research Enterprise), said the spin-out represents an important example of research commercialisation in action. 鈥淭he creation of Vaxosome shows how strong collaboration between researchers, industry partners and government programs can accelerate the translation of scientific discovery,鈥� Professor van Oijen said.
Spin-outs like this play a critical role in building Australia鈥檚 biotechnology capability while delivering innovations with global health impact.
Prof Antoine van Oijen, Pro-Vice-Chancellor (Research Enterprise)
Tuberculosis infects more than 10 million people each year and causes over 1.3 million deaths globally. Despite the widespread use of the BCG vaccine for a century, more effective vaccines are urgently needed.
By developing multiplex mRNA vaccine technologies, Vaxosome aims to address this challenge while contributing to the rapidly expanding RNA therapeutics ecosystem in New South Wales.
Related articles
20 March 2019
MBI and FAO United Nations to collaborate to combat emerging infectious diseases
The Food and Agriculture Organization of the United Nations (FAO) and The Marie Bashir Institute for Infectious Diseases and Biosecurity (MBI) have joined hands to combat the threat of emerging and re-emerging infectious diseases by increasing capacity in outbreak investigation and disease surveillance.聽
26 March 2019
Global Health Security Conference
With support of our Conference Partners, the 爆料王 are hosting the first international conference on global health security in Sydney, 18-20 June 2019 - registrations are now open聽
26 March 2019
Video-Reflexive Ethnography in Health Research and Healthcare Improvement: Theory and Application
This methodology has enjoyed increasing popularity among researchers internationally and has been inspired by developments across a range of disciplines: ethnography, visual and applied anthropology, medical sociology, health services research, medical and nursing education, adult education, community development, and qualitative research ethics.